Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27827433 | 0.98 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL6050465 | 0.84 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL27827436 | 0.81 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4553207 | 0.81 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL19946898 | 0.80 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL19946897 | 0.80 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL28241871 | 0.76 | EPHX2 (0.49) | TSHR | |
| Hydrochloric Acid SCHEMBL28241080 | 0.74 | EPHX2 (0.47) | TSHR | |
| SCHEMBL15635204 | 0.73 | SLC6A3 (0.40) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL9353322 | 0.73 | SLC6A2 (0.50) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2344457-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| EP-2260043-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal Gmbh (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009124746-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | SLC6A3 1075/4885SLC6A2 923/4885SLC6A4 1046/4885 |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | BDKRB2, BDKRB1, TRPV1 | SLC6A3 2110/4885SLC6A2 1412/4885SLC6A4 1195/4885 |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | SLC6A3 2108/4885SLC6A2 1443/4885SLC6A4 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.